25.73
0.12 (0.47%)
| Penutupan Terdahulu | 25.61 |
| Buka | 26.42 |
| Jumlah Dagangan | 840,351 |
| Purata Dagangan (3B) | 1,012,166 |
| Modal Pasaran | 2,618,439,168 |
| Harga / Buku (P/B) | 4.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Mar 2025 - 7 Mar 2025 |
| EPS Cair (TTM) | -3.58 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.52% |
| Nisbah Semasa (MRQ) | 17.02 |
| Aliran Tunai Operasi (OCF TTM) | -243.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -144.04 M |
| Pulangan Atas Aset (ROA TTM) | -40.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -68.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Dyne Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.10 |
|
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.49% |
| % Dimiliki oleh Institusi | 112.41% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (HC Wainwright & Co., 113.76%) | Beli |
| Median | 48.00 (86.55%) | |
| Rendah | 35.00 (JP Morgan, 36.03%) | Pegang |
| Purata | 47.33 (83.95%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 31.49 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 13 Dec 2024 | 46.00 (78.78%) | Beli | 25.73 |
| RBC Capital | 26 Nov 2024 | 45.00 (74.89%) | Beli | 29.23 |
| Chardan Capital | 13 Nov 2024 | 50.00 (94.33%) | Beli | 34.13 |
| HC Wainwright & Co. | 13 Nov 2024 | 55.00 (113.76%) | Beli | 34.13 |
| JP Morgan | 24 Oct 2024 | 35.00 (36.03%) | Pegang | 31.10 |
| Piper Sandler | 23 Sep 2024 | 53.00 (105.99%) | Beli | 34.63 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KERSTEN DIRK | - | 28.67 | -34,437 | -987,309 |
| Jumlah Keseluruhan Kuantiti Bersih | -34,437 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -987,309 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 28.67 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KERSTEN DIRK | Pengarah | 09 Dec 2024 | Jual (-) | 34,437 | 28.67 | 987,309 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2024 | Pengumuman | Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 07 Nov 2024 | Pengumuman | Dyne Therapeutics to Present at Upcoming Investor Conferences |
| 09 Oct 2024 | Pengumuman | Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases |
| 23 Sep 2024 | Pengumuman | Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |